Welcome to our dedicated page for Apyx Medical Corporation SEC filings (Ticker: APYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apyx Medical Corporation filings document regulatory disclosures for a surgical aesthetics medical-device issuer. Recent Form 8-K reports cover results of operations, preliminary revenue releases, FDA 510(k) clearance updates for the AYON Body Contouring System, and exhibits tied to company press releases.
The filing record also includes capital-structure and governance disclosures, including an underwritten common stock offering, amendments to the certificate of incorporation, annual meeting voting results, director elections, auditor ratification, executive compensation advisory votes, and related proxy matters.
Apyx Medical Corp Chief Operating Officer Shawn David Roman reported a net stock option exercise through The Roman Family Revocable Trust. On June 15, 2026, he exercised 15,000 stock options at an exercise price of $3.23 per share.
To cover the aggregate exercise price, 10,533 shares of common stock otherwise issuable were withheld by the issuer at a value of $4.60 per share as a tax and exercise-price payment. As a result, 4,467 net shares of common stock were issued to the trust. Following the tax-withholding disposition, the trust held 16,467 shares of Apyx Medical common stock indirectly for the reporting person.
Apyx Medical Corporation has appointed Board Chairman Stavros Vizirgianakis as Executive Chairman under a new letter agreement dated June 11, 2026. In this role, he will provide strategic leadership, governance oversight, support for corporate initiatives, investor engagement, and advice on capital markets and corporate development.
In connection with this appointment and in recognition of his service, the Board granted Mr. Vizirgianakis 450,000 restricted stock units under the 2023 Share Incentive Plan. Of these, 150,000 RSUs vest immediately on June 11, 2026, with two additional tranches of 150,000 RSUs each vesting monthly over 12-month periods starting on the first and second anniversaries of the grant date. He will not be an officer or "executive officer" of the company.
Apyx Medical Corp director Wendy Lauren Levine received a grant of stock options as part of her compensation. She was awarded options to purchase 50,000 shares of Apyx common stock at an exercise price of $4.65 per share, expiring on June 11, 2036. According to the disclosure, the option grant vests ratably over a twelve-month period and becomes fully vested and exercisable on the first anniversary of the grant date. After this award, she holds 50,000 stock options directly.
Vizirgianakis Stavros G. reported acquisition or exercise transactions in this Form 4 filing.
Apyx Medical Corp director Stavros G. Vizirgianakis received a grant of 450,000 restricted stock units (RSUs). The award was granted at no cash cost per unit and is compensation rather than an open-market purchase.
According to the vesting schedule, 150,000 RSUs vest on June 11, 2026, 150,000 begin vesting on the first anniversary of that date and vest ratably over the following twelve months, and the remaining 150,000 follow the same ratable schedule starting on the second anniversary. After this grant, Vizirgianakis directly holds 2,196,191 shares or share-equivalents reported in this filing.
Apyx Medical Corp disclosed that Chief Executive Officer Charles D. Goodwin II received a grant of stock options for 213,948 shares of common stock. The options have an exercise price of $4.65 per share, vest ratably over 36 months, and become fully exercisable on the third anniversary of the grant date.
Apyx Medical Corp reported that Chief Operating Officer Shawn David Roman received a grant of stock options on Common Stock. The award covers 88,044 underlying shares with an exercise price of $4.65 per share and expires on June 11, 2036.
The options were granted as compensation and will vest ratably over 36 months, becoming fully vested and exercisable on the third anniversary of the grant date. Following this award, Roman holds 88,044 stock options directly, with no open-market share purchases or sales disclosed in this filing.
Apyx Medical Corp director Minnie Baylor-Henry received a compensatory stock option grant for 50,000 shares of common stock on June 11, 2026. The option has an exercise price of $4.65 per share and expires on June 11, 2036.
The option vests ratably over a twelve-month period and becomes fully vested and exercisable on the first anniversary of the grant date. Following this award, the filing shows 50,000 derivative securities (options) held directly.
Apyx Medical Corp director Lawrence Waldman received a grant of stock options as compensation. He was awarded options to buy 50,000 shares of common stock at an exercise price of $4.6500 per share, expiring on June 11, 2036. According to the terms, the option vests ratably over a 12‑month period and becomes fully vested and fully exercisable on the first anniversary of the grant date. Following this award, Waldman holds 50,000 stock options directly under this grant.
Apyx Medical Corp reported that Chief Financial Officer Matthew C. Hill received a grant of stock options as part of his compensation. The award covers 132,066 options to buy common stock at an exercise price of $4.65 per share, expiring on June 11, 2036. According to the disclosure, these options vest ratably over a thirty-six month period and become fully vested and exercisable on the third anniversary of the grant date. Following this grant, Hill holds 132,066 stock options directly, and the filing shows no open-market purchases or sales.
Apyx Medical Corp reported that Sr. V.P. of Operations Moshe Citronowicz received a grant of stock options. The award covers 63,392 options to buy common stock at an exercise price of $4.65 per share, expiring on June 11, 2036.
According to the disclosure, these options were granted at no cost and will vest ratably over 36 months, becoming fully vested and exercisable on the third anniversary of the grant date. Following this grant, the filing shows beneficial ownership of 63,392 derivative securities directly held as options.